Provided are an RSV F protein mutant, a nucleic acid molecule or a vector encoding the RSV F protein mutant, an immunogenic composition comprising the RSV F protein mutant, the nucleic acid molecule, or the vector, and use thereof. The RSV F mutant can bind, with high affinity, to a preF-specific neutralizing antibody, but it basically does not bind to an antibody that specifically binds to a postF protein.
The present invention relates to chimeric papilloma virus L1 proteins and polynucleotides encoding thereof, and also to HPV virus-like particles and the preparation methods thereof. Said chimeric papilloma virus L1 protein comprises an N-terminal fragment derived from L1 protein of the first papilloma virus type, said N-terminal fragment maintains the immunogenicity of the L1 protein of the corresponding type of HPV; and a C-terminal fragment derived from L1 protein of the second papilloma virus type, said L1 protein of the second papilloma virus type has a better expression level and a better solubility compared to the L1 proteins of other HPV types; wherein said chimeric papilloma virus L1 proteins have the immunogenicity of the L1 proteins of the corresponding HPV types. Said chimeric papilloma virus L proteins have better expression amount and solubility for mass production of vaccines.
The present invention relates to chimeric papilloma virus L1 proteins and polynucleotides encoding thereof, and also to HPV virus-like particles and the preparation methods thereof. Said chimeric papilloma virus L1 protein comprises an N-terminal fragment derived from L1 protein of the first papilloma virus type, said N-terminal fragment maintains the immunogenicity of the L1 protein of the corresponding type of HPV; and a C-terminal fragment derived from L1 protein of the second papilloma virus type, said L1 protein of the second papilloma virus type has a better expression level and a better solubility compared to the L1 proteins of other HPV types; wherein said chimeric papilloma virus L1 proteins have the immunogenicity of the L1 proteins of the corresponding HPV types. Said chimeric papilloma virus L proteins have better expression amount and solubility for mass production of vaccines.
The present invention relates to chimeric papilloma virus L1 proteins and polynucleotides encoding thereof, and also to HPV virus-like particles and the preparation methods thereof. Said chimeric papilloma virus L1 protein comprises an N-terminal fragment derived from L1 protein of the first papilloma virus type, said N-terminal fragment maintains the immunogenicity of the L1 protein of the corresponding type of HPV; and a C-terminal fragment derived from L1 protein of the second papilloma virus type, said L1 protein of the second papilloma virus type has a better expression level and a better solubility compared to the L1 proteins of other HPV types; wherein said chimeric papilloma virus L1 proteins have the immunogenicity of the L1 proteins of the corresponding HPV types. Said chimeric papilloma virus L proteins have better expression amount and solubility for mass production of vaccines.
The present invention relates to chimeric papilloma virus L1 proteins and polynucleotides encoding thereof, and also to HPV virus-like particles and the preparation methods thereof. Said chimeric papilloma virus L1 protein comprises an N-terminal fragment derived from L1 protein of the first papilloma virus type, said N-terminal fragment maintains the immunogenicity of the L1 protein of the corresponding type of HPV; and a C-terminal fragment derived from L1 protein of the second papilloma virus type, said L1 protein of the second papilloma virus type has a better expression level and a better solubility compared to the L1 proteins of other HPV types; wherein said chimeric papilloma virus L1 proteins have the immunogenicity of the L1 proteins of the corresponding HPV types. Said chimeric papilloma virus L proteins have better expression amount and solubility for mass production of vaccines.
The present invention relates to chimeric papilloma virus L1 proteins and polynucleotides encoding thereof, and also to HPV virus-like particles and the preparation methods thereof. Said chimeric papilloma virus L1 protein comprises an N-terminal fragment derived from L1 protein of the first papilloma virus type, said N-terminal fragment maintains the immunogenicity of the L1 protein of the corresponding type of HPV; and a C-terminal fragment derived from L1 protein of the second papilloma virus type, said L1 protein of the second papilloma virus type has a better expression level and a better solubility compared to the L1 proteins of other HPV types; wherein said chimeric papilloma virus L1 proteins have the immunogenicity of the L1 proteins of the corresponding HPV types. Said chimeric papilloma virus L proteins have better expression amount and solubility for mass production of vaccines.
The present invention relates to chimeric papilloma virus L1 proteins and polynucleotides encoding thereof, and also to HPV virus-like particles and the preparation methods thereof. Said chimeric papilloma virus L1 protein comprises an N-terminal fragment derived from L1 protein of the first papilloma virus type, said N-terminal fragment maintains the immunogenicity of the L1 protein of the corresponding type of HPV; and a C-terminal fragment derived from L1 protein of the second papilloma virus type, said L1 protein of the second papilloma virus type has a better expression level and a better solubility compared to the L1 proteins of other HPV types; wherein said chimeric papilloma virus L1 proteins have the immunogenicity of the L1 proteins of the corresponding HPV types. Said chimeric papilloma virus L proteins have better expression amount and solubility for mass production of vaccines.
The present invention relates to chimeric papilloma virus L1 proteins and polynucleotides encoding thereof, and also to HPV virus-like particles and the preparation methods thereof. Said chimeric papilloma virus L1 protein comprises an N-terminal fragment derived from L1 protein of the first papilloma virus type, said N-terminal fragment maintains the immunogenicity of the L1 protein of the corresponding type of HPV; and a C-terminal fragment derived from L1 protein of the second papilloma virus type, said L1 protein of the second papilloma virus type has a better expression level and a better solubility compared to the L1 proteins of other HPV types; wherein said chimeric papilloma virus L1 proteins have the immunogenicity of the L1 proteins of the corresponding HPV types. Said chimeric papilloma virus L proteins have better expression amount and solubility for mass production of vaccines.
The present invention relates to chimeric papilloma virus L1 proteins and polynucleotides encoding thereof, and also to HPV virus-like particles and the preparation methods thereof. Said chimeric papilloma virus L1 protein comprises an N-terminal fragment derived from L1 protein of the first papilloma virus type, said N-terminal fragment maintains the immunogenicity of the L1 protein of the corresponding type of HPV; and a C-terminal fragment derived from L1 protein of the second papilloma virus type, said L1 protein of the second papilloma virus type has a better expression level and a better solubility compared to the L1 proteins of other HPV types; wherein said chimeric papilloma virus L1 proteins have the immunogenicity of the L1 proteins of the corresponding HPV types. Said chimeric papilloma virus L proteins have better expression amount and solubility for mass production of vaccines.
The present invention relates to chimeric papilloma virus L1 proteins and polynucleotides encoding thereof, and also to HPV virus-like particles and the preparation methods thereof. Said chimeric papilloma virus L1 protein comprises an N-terminal fragment derived from L1 protein of the first papilloma virus type, said N-terminal fragment maintains the immunogenicity of the L1 protein of the corresponding type of HPV; and a C-terminal fragment derived from L1 protein of the second papilloma virus type, said L1 protein of the second papilloma virus type has a better expression level and a better solubility compared to the L1 proteins of other HPV types; wherein said chimeric papilloma virus L1 proteins have the immunogenicity of the L1 proteins of the corresponding HPV types. Said chimeric papilloma virus L proteins have better expression amount and solubility for mass production of vaccines.
The present invention relates to chimeric papilloma virus L1 proteins and polynucleotides encoding thereof, and also to HPV virus-like particles and the preparation methods thereof. Said chimeric papilloma virus L1 protein comprises an N-terminal fragment derived from L1 protein of the first papilloma virus type, said N-terminal fragment maintains the immunogenicity of the L1 protein of the corresponding type of HPV; and a C-terminal fragment derived from L1 protein of the second papilloma virus type, said L1 protein of the second papilloma virus type has a better expression level and a better solubility compared to the L1 proteins of other HPV types; wherein said chimeric papilloma virus L1 proteins have the immunogenicity of the L1 proteins of the corresponding HPV types. Said chimeric papilloma virus L proteins have better expression amount and solubility for mass production of vaccines.
The present invention relates to chimeric papilloma virus L1 proteins and polynucleotides encoding thereof, and also to HPV virus-like particles and the preparation methods thereof. Said chimeric papilloma virus L1 protein comprises an N-terminal fragment derived from L1 protein of the first papilloma virus type, said N-terminal fragment maintains the immunogenicity of the L1 protein of the corresponding type of HPV; and a C-terminal fragment derived from L1 protein of the second papilloma virus type, said L1 protein of the second papilloma virus type has a better expression level and a better solubility compared to the L1 proteins of other HPV types; wherein said chimeric papilloma virus L1 proteins have the immunogenicity of the L1 proteins of the corresponding HPV types. Said chimeric papilloma virus L proteins have better expression amount and solubility for mass production of vaccines.
Provided is a stable formulation of a human papillomavirus virus-like particle vaccine. The stable formulation is composed of a human papillomavirus virus-like particle, a buffer solution, an osmotic pressure regulator, a surfactant and an aluminum adjuvant, wherein the components of the vaccine comprise HPV virus-like particles assembled by L1 proteins of HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58, and one or more HPV virus-like particles assembled by L1 proteins of other pathogenic HPV types. The formulation can enhance the stability of the vaccine and prolong the validity period of the vaccine in an aqueous formulation.
The present invention relates to the field of molecular vaccinology. Provided is a recombinant multi-component SARS-CoV-2 trimer protein vaccine capable of inducing broad-spectrum neutralization activity. The components of a recombinant protein comprise, but are not limited to, a homotrimer protein which is formed by introducing mutation sites and trimerization auxiliary structures into the extracellular domains (ECD) of spike proteins (S protein) of Alpha (B.1.1.7), Beta (B.1.351), Delta (B.1.617.2) and Omicron (BA.1, BA.4/BA.5). The multi-component vaccine comprises the ECD trimer protein of a single component or any combined components of the variants and a pharmaceutically acceptable adjuvant. The vaccine combination shows excellent immunogenicity in mice, and can maintain long-term humoral immune and cellular immune responses. The multi-component SARS-CoV-2 trimer protein vaccine can be used for preventing infection-related diseases caused by infection of SARS-CoV-2 and the variants thereof.
Streptococcus pneumonia. The conjugate with improved immunogenicity can be used to prevent or treat diseases caused by pathogens, in particular diseases caused by coronaviruses.
The present invention relates to the field of molecular vaccinology. Provided in the present invention is a recombinant multicomponent SARS-CoV-2 trimeric protein vaccine capable of inducing a broad-spectrum neutralizing activity. Recombinant protein ingredients include, but are not limited to, homotrimeric proteins formed by means of introducing mutation sites and trimeric auxiliary structures to the extracellular domains (ECD) of spike proteins (S proteins) of Alpha (B.1.1.7), Beta (B.1.351), Delta (B.1.617.2) and BA.1 (B.1.1.529.1). The multicomponent vaccine contains an ECD trimeric protein of the above variants, either alone or in any combination, and a pharmaceutically acceptable adjuvant. The vaccine combination shows excellent immunogenicity in mice, while also maintaining long-term humoral immunity and cellular immune responses. The multicomponent SARS-CoV-2 trimeric protein vaccine can be used for preventing infection-related diseases caused by infections with SARS-CoV-2 and variants thereof.
Provided is a stable formulation for a recombinant monoclonal antibody, consisting of a recombinant anti-PD-1 monoclonal antibody, a buffer, an osmotic pressure regulator, a stabilizer, and a surfactant. The pharmaceutical formulation may enhance the stability of the antibody and prolongs a validity period of the antibody in aqueous formulations.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 9/19 - Particulate form, e.g. powders lyophilised
18.
TGFßR2 EXTRACELLULAR DOMAIN TRUNCATED MOLECULE, FUSION PROTEIN OF TGFßR2 EXTRACELLULAR DOMAIN TRUNCATED MOLECULE AND ANTI-EGFR ANTIBODY, AND ANTI-TUMOR USE OF FUSION PROTEIN
Provided are multiple types of TGFβR2 in truncated forms and a fusion protein constructed by TGFβR2 and EGFR antibody HPA8; also provided are a nucleic acid (comprising heavy/light chain variable regions) encoding the antibody, a vector, a pharmaceutical composition, and a kit comprising the nucleic acid; further provided is a fusion protein of the prepared truncated TGFβR2 receptor protein and a targeted EGFR and other multiple types of tumor target antibodies.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 14/71 - ReceptorsCell surface antigensCell surface determinants for growth factorsReceptorsCell surface antigensCell surface determinants for growth regulators
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
19.
PREPARATION AND APPLICATION OF RECOMBINANT MULTIVALENT NOVEL CORONAVIRUS TRIMER PROTEIN VACCINE CAPABLE OF INDUCING BROAD-SPECTRUM AND NEUTRALIZING ACTIVITY
A recombinant multivalent novel coronavirus trimer protein vaccine capable of inducing broad-spectrum and neutralizing activity. The recombinant protein component comprises, but is not limited to, a homotrimer protein formed by introducing, into an extracellular domain (ECD) of B.1.617.1 strain and B.1.617.2 strain spike (S) proteins, a mutation site and a trimerization assistance structure. The multivalent vaccine comprises an ECD trimer protein of a single component or any combination of components of the variant strains above, and a pharmaceutically acceptable adjuvant. The vaccine combination shows excellent immunogenicity in mice, and can maintain long-term humoral immunity and cellular immunity. The multivalent novel coronavirus trimer protein vaccine can be used for preventing infection-related diseases caused by infection of novel coronavirus and variant strains thereof.
The present invention relates to the field of molecular vaccinology, and provides a method for improving the immunogenicity/antigenic trimer stability of an extracellular domain (ECD) antigen of a SARS-CoV-2 mutant strain, and an ECD immunogenic protein/peptide, having improved immunogenicity/antigenic trimer stability, of the SARS-CoV-2 mutant strain. The present invention comprises, but is not limited to, an ECD of a spike protein (S protein) of a SARS-CoV-2 strain, a B.1 strain, a B.1.1.7 strain or a B.1.351 strain having a genome sequence number of GenBank Accession No. MN908947.3; by introducing a homotrimer formed by a mutation site and a trimerization-assisted structure, the immunogenicity/antigenic trimer stability of the ECD antigen is improved. A vaccine further comprises a pharmaceutically acceptable adjuvant. A vaccine composition exhibits excellent immunogenicity in mice and Macaca fascicularis, and can maintain long-term humoral and cellular immune responses. A recombinant trimer protein vaccine can be used for preventing diseases related to SARS-CoV-2 infections.
The present invention relates to a multivalent HPV immunogenic composition for preventing human papillomavirus (HPV) related diseases or infections and uses thereof. Said multivalent HPV immunogenic composition comprises: HPV virus-like particles assembled from L1 proteins of HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58; and one or more HPV virus-like particles assembled from L1 proteins of other pathogenic HPV types. In one embodiment, said one or more other pathogenic HPV types are selected from HPV Types 35, 39, 51, 56 and 59. In one embodiment, at least one of said HPV virus-like particles is a chimeric HPV virus-like particle, and said chimeric HPV virus-like particle comprises one or more chimeric HPV L1 proteins.
The present invention relates to chimeric papilloma virus L1 proteins and polynucleotides encoding thereof, and also to HPV virus-like particles and the preparation methods thereof. Said chimeric papilloma virus L1 protein comprises an N-terminal fragment derived from L1 protein of the first papilloma virus type, said N-terminal fragment maintains the immunogenicity of the L1 protein of the corresponding type of HPV; and a C-terminal fragment derived from L1 protein of the second papilloma virus type, said L1 protein of the second papilloma virus type has a better expression level and a better solubility compared to the L1 proteins of other HPV types; wherein said chimeric papilloma virus L1 proteins have the immunogenicity of the L1 proteins of the corresponding HPV types. Said chimeric papilloma virus L proteins have better expression amount and solubility for mass production of vaccines.
The present disclosure relates to a multiple-variable dosage regimen for the treatment of cancers with high expression of EGFR. Particularly, the present disclosure relates to a multiple-variable dosage regimen for treating cancers with high EGFR expression in a subject in need, comprising: administering a first dose of anti-EGFR antibody or antigen-binding fragment thereof to said subject in a first treatment cycle; and subsequently administering a second dose of anti-EGFR antibody or antigen-binding fragment thereof to said subject during the second treatment cycle. The regimen described in the present disclosure realizes favorable effects to cancer treatment.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 35/04 - Antineoplastic agents specific for metastasis
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Vaccines; medicines for human purposes; biological
preparations for medical purposes; biological preparations
for the treatment of cancer; pharmaceutical preparations for
the treatment of immune system related diseases and
disorders; chemical reagents for medical or veterinary
purposes; medicines for veterinary purposes; dietetic
substances adapted for medical use; medical diagnostic
reagents; blood for medical purposes.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Vaccines; medicines for human purposes; biological
preparations for medical purposes; biological preparations
for the treatment of cancer; pharmaceutical preparations for
the treatment of immune system related diseases and
disorders; chemical reagents for medical or veterinary
purposes; medicines for veterinary purposes; dietetic
substances adapted for medical use; medical diagnostic
reagents; blood for medical purposes.
26.
STABLE PREPARATION OF HUMAN PAPILLOMAVIRUS VIRUS-LIKE PARTICLE VACCINE
Provided is a stable preparation of a human papillomavirus virus-like particle vaccine. The stable preparation is composed of a human papillomavirus virus-like particle, a buffer solution, an osmotic pressure regulator, a surfactant and an aluminum adjuvant, wherein the components of the vaccine comprise HPV virus-like particles assembled by L1 proteins of HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58, and one or more HPV virus-like particles assembled by L1 proteins of other pathogenic HPV types. The preparation can enhance the stability of the vaccine and prolong the validity period of the vaccine in an aqueous preparation.
Provided is a stable preparation of a human papillomavirus virus-like particle vaccine. The stable preparation is composed of a human papillomavirus virus-like particle, a buffer solution, an osmotic pressure regulator, a surfactant and an aluminum adjuvant, wherein the components of the vaccine comprise HPV virus-like particles assembled by L1 proteins of HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58, and one or more HPV virus-like particles assembled by L1 proteins of other pathogenic HPV types. The preparation can enhance the stability of the vaccine and prolong the validity period of the vaccine in an aqueous preparation.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Vaccines; medicines for human purposes; biological
preparations for medical purposes; biological preparations
for the treatment of cancer; pharmaceutical preparations for
the treatment of immune system related diseases and
disorders; chemical reagents for medical or veterinary
purposes; medicines for veterinary purposes; dietetic
substances adapted for medical use; medical diagnostic
reagents; blood products.
The present invention belongs to the field of tumor immunotherapy, and relates to a humanized monoclonal antibody that binds to VEGF. The present invention discloses nucleic acid sequences (including heavy/light chain variable regions) encoding said antibodies, and vectors, pharmaceutical compositions and kits containing said nucleic acid sequences. The antibody disclosed in the present invention can specifically bind to VEGF with high affinity and block the binding of VEGF to the receptor VEGFR2. Said antibodies also neutralize the proliferative effect of VEGF165 protein and multiple VEGF subtypes on HUVEC cells and can be used in clinical treatment of tumors, including but not limited to: colorectal cancer.
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
30.
Humanized anti-IL17A antibody and application thereof
The present invention belongs to the field of immunotherapy of autoimmune diseases and relates to a humanized monoclonal antibody that binds IL17A. The present invention discloses a nucleic acid sequence encoding said antibody, a vector containing said nucleic acid sequences, a pharmaceutical composition and a kit. Said monoclonal antibody is capable of specifically binding IL17A protein with high affinity, has a strong ability to block the binding of IL17A, IL17A/F with receptor IL17RA. The humanized monoclonal antibody of the present invention can be used for the treatment of psoriasis, etc.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The present invention belongs to the field of tumor immunotherapy, and relates to a humanized anti-VEGF antibody Fab fragment. The present invention discloses nucleic acid sequences (including heavy/light chain variable regions) encoding said antibody fragment, and vectors, pharmaceutical compositions and kits containing said nucleic acid sequences. The anti-VEGF antibody Fab fragments disclosed in the present invention can specifically bind to VEGF with high affinity and block the binding of VEGF to the receptor VEGFR2, and also neutralize the proliferative effect of VEGF on HUVEC cells. Compared to the full-length antibody, antibodies in the form of Fab fragments have stronger penetrability and less toxic in terms of gastrointestinal perforation, hypertension and hemorrhage and do not stimulate the complement cascade reaction, thus reducing the risk of endophthalmitis and autoimmune inflammatory reactions. Thus it could be used in clinical treatment of ocular diseases characterized by choroidal neovascularization, including but not limited to age-related macular degeneration (AMD), diabetic macular edema (DME), retinal edema, degenerative myopia, choroidal neovascularization (CNV).
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Vaccines; medicines for human purpose, namely pharmaceutical preparations for the treatment of genetic and immune system diseases and disorders, cancer, ophthalmic diseases and conditions, infectious diseases; biological preparations, namely pharmaceutical preparations for the treatment of genetic and immune system diseases and disorders, cancer, ophthalmic diseases and conditions, infectious diseases; biological preparations for the treatment of cancer; pharmaceutical preparations for the treatment of immune system related diseases and disorders; chemical reagents for medical or veterinary purposes; dietetic beverages and foods adapted for medical use; medical diagnostic reagents; blood products, namely blood for medical purposes
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Vaccines; medicines for human purpose, namely pharmaceutical preparations for the treatment of genetic and immune system diseases and disorders, cancer, ophthalmic diseases and conditions, infectious diseases; biological preparations, namely pharmaceutical preparations for the treatment of genetic and immune system diseases and disorders, cancer, ophthalmic diseases and conditions, infectious diseases; biological preparations for the treatment of cancer; pharmaceutical preparations for the treatment of immune system related diseases and disorders; chemical reagents for medical or veterinary purposes; dietetic beverages and foods adapted for medical use; medical diagnostic reagents; blood for medical purposes
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Vaccines; medicines for human purpose, namely, pharmaceutical preparations for the treatment of genetic and immune system diseases and disorders, cancer, ophthalmic diseases and conditions, infectious diseases; biological preparations for the treatment of cancer; biological preparations, namely, pharmaceutical preparations for the treatment of genetic and immune system diseases and disorders, cancer, ophthalmic diseases and conditions, infectious diseases; pharmaceutical preparations for the treatment of immune system related diseases and disorders; chemical reagents for medical or veterinary purposes; dietetic beverages and foods adapted for medical use; medical diagnostic reagents; blood for medical purposes
35.
METHOD FOR IMPROVING IMMUNOGENICITY BY USING GLYCO-CORONAVIRUS RBD ANTIGEN CONJUGATE
A method for improving the immunogenicity of a coronavirus RBD, a glyco-coronavirus RBD antigen conjugate and an immunogenic complex comprising the antigen conjugate. Specifically, the glyco-coronavirus RBD protein conjugate is formed by an RBD truncated protein having better stability and pneumonia polysaccharide; and after immunizing animals with the glyco-coronavirus RBD protein conjugate as an immunogen, long-term humoral and cellular immune responses can be maintained. An immune complex formed by the glyco-coronavirus RBD protein conjugate and an MF59 adjuvant can produce a neutralization antibody and a cellular immune response having higher potency. The immunogenic complex can be used for preventing diseases associated with coronavirus (e.g, SARS-CoV-2) infection.
The present disclosure provides a recombinant humanized monoclonal antibody against programmed cell death receptor-1 (PD-1) or an antigen-binding fragment thereof, which can be used in tumor or cancer immunotherapy. The disclosure also provides nucleic acid sequences encoding said antibody or antigen-binding fragment thereof, vectors containing said nucleic acid sequences, pharmaceutical compositions and kits.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
Provided is a method for reducing a viral ADE effect. The method achieves the purpose thereof by administering molecules that reduce the viral ADE effect to a subject who is infected by a virus or who is at risk of being infected by a virus. By performing a molecular biology modification on an Fc fragment of an antibody, an Fc fragment having reduced Fc receptor binding/complement binding performance is obtained. The antibody containing the Fc fragment can reduce the viral ADE effect. The antibody is preferably used to prevent and/or treat acute respiratory infections caused by a coronavirus infection.
Provided is a stable formulation for a recombinant monoclonal antibody, consisting of a recombinant anti-PD-1 monoclonal antibody, a buffer, an osmotic pressure regulator, a stabilizer, and a surfactant. The pharmaceutical formulation may enhance the stability of the antibody and prolongs a validity period of the antibody in aqueous formulations. Fig.8 is elected to be the abstract figure.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
39.
STABLE FORMULATION FOR RECOMBINANT ANTI-PD-1 MONOCLONAL ANTIBODY
Provided is a stable formulation for a recombinant monoclonal antibody, consisting of a recombinant anti-PD-1 monoclonal antibody, a buffer, an osmotic pressure regulator, a stabilizer, and a surfactant. The pharmaceutical formulation may enhance the stability of the antibody, and prolongs a validity period of the antibody in aqueous formulations.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A method for enhancing the immunogenicity of a protein/peptide antigen, wherein the protein/peptide antigen forms a fusion protein with a modified antibody Fc fragment, and the Fc fragment has an improved binding capacity to an Fc receptor and/or a complement protein C1q compared with the natural form thereof due to changes in the amino acid sequence and/or the glycosylation form thereof. The SARS-CoV-2 vaccine prepared by means of using the fusion protein as an immunogen has a high binding capacity to the Fc receptor, and can maintain long-term humoral and cellular immune responses, and immunized animals can produce higher titers of neutralizing antibodies. The recombinant protein vaccine can be used to prevent SARS-CoV-2 infection-related diseases.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
41.
METHOD FOR ENHANCING IMMUNOGENICITY OF ANTIGEN BY FORMING FC FRAGMENT FUSION PROTEIN GLYCOCONJUGATE
Provided is a method for enhancing immunogenicity of a protein/peptide antigen. The protein/peptide antigen forms a fusion protein with an Fc fragment, preferably a receptor binding/complement binding enhanced Fc fragment, and is further conjugated to sugar to form a fusion protein glycoconjugate. In the preferable solution, the Fc fragment has improved binding ability to an Fc receptor and/or complement protein C1q due to changes in an amino acid sequence and/or glycosylation form thereof as compared with the natural form thereof. The vaccine can maintain a long-term humoral and cellular immune response, and has a stronger cellular immune response, and an immunize animal can produce a neutralizing antibody having a higher titer. A SARS-CoV-2 RBD region is taken as an antigen of an immune composition, and the antigen forms a fusion protein with an Fc region of which amino acid sequence and fucose are altered, and further forms a fusion protein glycoconjugate with pneumococcal polysaccharide, thereby preventing SARS-CoV-2 infection related diseases.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
vaccines; medicines for human purpose, namely, pharmaceutical preparations for the treatment of genetic and immune system diseases and disorders, cancer, ophthalmic diseases and conditions, infectious diseases; biological preparations, namely, pharmaceutical preparations for the treatment of genetic and immune system diseases and disorders, cancer, ophthalmic diseases and conditions, infectious diseases; biological preparations for the treatment of cancer; pharmaceutical preparations for the treatment of immune system related diseases and disorders; chemical reagents for medical or veterinary purposes; dietetic beverages and foods adapted for medical use; medical diagnostic reagents; blood products, namely, blood for medical purposes
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
vaccines; medicines for human purpose, namely, pharmaceutical preparations for the treatment of genetic and immune system diseases and disorders, cancer, ophthalmic diseases and conditions, infectious diseases; biological preparations, namely, pharmaceutical preparations for the treatment of genetic and immune system diseases and disorders, cancer, ophthalmic diseases and conditions, infectious diseases; biological preparations for the treatment of cancer; pharmaceutical preparations for the treatment of immune system related diseases and disorders; chemical reagents for medical or veterinary purposes; dietetic beverages and foods adapted for medical use; medical diagnostic reagents; blood products, namely, blood for medical purposes
44.
TGFBR2 EXTRACELLULAR DOMAIN TRUNCATED MOLECULE, FUSION PROTEIN OF TGFBR2 EXTRACELLULAR DOMAIN TRUNCATED MOLECULE AND ANTI-EGFR ANTIBODY, AND ANTI-TUMOR USE OF FUSION PROTEIN
Provided are multiple types of TGFR2 in truncated forms and a fusion protein constructed by TGFR2 and EGFR antibody HPA8; also provided are a nucleic acid (comprising heavy/light chain variable regions) encoding the antibody, and a vector, a pharmaceutical composition, and a kit comprising the nucleic acid; further provided is a fusion protein of the prepared truncated form of TGFR2 receptor protein and a targeted EGFR and other multiple types of tumor target antibodies.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
Disclosed is a method for improving the immunogenicity of a protein/peptide antigen, the method comprising conjugating a protein/peptide antigen with a sugar to form a sugar-protein/peptide antigen conjugate, which has improved immunogenicity compared to an unconjugated protein/peptide antigen. In particular, the method involves conjugating a pathogen, such as a viral surface protein antigen or a fragment thereof, with a polysaccharide, in particular a capsular polysaccharide of Streptococcus pneumoniae. The conjugate with improved immunogenicity can be used to prevent or treat diseases caused by pathogens, in particular diseases caused by coronaviruses.
Disclosed is a method for improving the immunogenicity of a protein/peptide antigen, the method comprising conjugating a protein/peptide antigen with a sugar to form a sugar-protein/peptide antigen conjugate, which has improved immunogenicity compared to an unconjugated protein/peptide antigen. In particular, the method involves conjugating a pathogen, such as a viral surface protein antigen or a fragment thereof, with a polysaccharide, in particular a capsular polysaccharide of Streptococcus pneumoniae. The conjugate with improved immunogenicity can be used to prevent or treat diseases caused by pathogens, in particular diseases caused by coronaviruses.
The present invention belongs to the field of cell immunity technology, and provides a SARS-CoV-2 neutralizing humanized monoclonal antibody. Said antibody can block the binding of an SARS-CoV-2 spike protein (S protein) and an ACE 2 receptor, and efficiently neutralize an invasion of cells by SARS-CoV-2 virus. The humanized neutralizing antibody prepared can be used as a specific antibody medicament for preventing and treating acute respiratory tract infectious diseases caused by the SARS-CoV-2 virus.
TGFβR2 EXTRACELLULAR DOMAIN TRUNCATED MOLECULE, FUSION PROTEIN OF TGFβR2 EXTRACELLULAR DOMAIN TRUNCATED MOLECULE AND ANTI-EGFR ANTIBODY, AND ANTI-TUMOR USE OF FUSION PROTEIN
Provided are multiple types of TGFβR2 in truncated forms and a fusion protein constructed by TGFβR2 and EGFR antibody HPA8; also provided are a nucleic acid (comprising heavy/light chain variable regions) encoding the antibody, and a vector, a pharmaceutical composition, and a kit comprising the nucleic acid; further provided is a fusion protein of the prepared truncated form of TGFβR2 receptor protein and a targeted EGFR and other multiple types of tumor target antibodies.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
Involved is the preparation of a plurality of cross-neutralizing humanized monoclonal antibodies. The antibodies can cross-block the binding of SARS-CoV-2 and SARS-CoV spike proteins (S proteins) to an ACE2 receptor, and efficiently neutralize cells infected by SARS-CoV-2 and SARS-CoV viruses. Provided are a nucleic acid sequence (comprising a heavy chain/light chain variable region) encoding the antibodies, a carrier comprising the nucleic acid sequence, a pharmaceutical composition, and a reagent kit. The prepared cross-neutralizing humanized antibodies can be used as a specific antibody medication for simultaneously preventing and treating an acute respiratory infectious disease caused by the SARS-CoV-2 and SARS-CoV viruses. The cross-neutralizing antibodies also have the function of diagnosis, etc.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Vaccines; biological preparations for medical purposes; biological preparations for the treatment of cancer; pharmaceutical preparations for the treatment of immune system related diseases and disorders; medical diagnostic reagents.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Vaccines; medicines for human purposes, namely medicines for the treatment of eye diseases and medicines for the treatment of genetic diseases; biological preparations for the treatment of cancer; pharmaceutical preparations for the treatment of immune system related diseases and disorders.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Vaccines; medicines for human purposes; biological preparations for medical purposes; biological preparations for the treatment of cancer; pharmaceutical preparations for the treatment of immune system related diseases and disorders; chemical reagents for medical or veterinary purposes; medicines for veterinary purposes; dietetic substances adapted for medical use; medical diagnostic reagents; blood products, including blood plasma.
Provided are a humanized monoclonal antibody that binds to TNFα, a nucleic acid sequence (comprising heavy/light chain variable regions) encoding the antibody, a vector containing the nucleic acid sequence, a pharmaceutical composition, and a kit. The monoclonal antibody can specifically bind to a secretory TNFα protein, retain an ADCC activity and a weaker CDC activity, and block the binding of the TNFα to receptors TNFR I and TNFR II, but only has a weak binding to a membrane-type TNFα protein on the cell membrane surface. In a mouse model for rheumatoid arthritis, the monoclonal antibody can effectively reduce the arthritis score. In the single-dose pharmacokinetics of Macaca fascicularis, the monoclonal antibody is sustained for a longer drug exposure period in vivo, and has a slow rate of decay.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
Provided are a humanized monoclonal antibody binding to IL 17A and a nucleic acid sequence (comprising heavy/light chain variable regions) encoding the antibody, a vector containing the nucleic acid sequence, a pharmaceutical composition and a kit. The monoclonal antibody can specifically bind to an IL 17A protein with a high affinity, has a stronger ability to block the binding of IL 17A and IL 17A/F to the receptor IL 17RA, and can be used for treating psoriasis, etc.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
Provided are a humanized monoclonal antibody binding to IL17A and a nucleic acid sequence (comprising heavy/light chain variable regions) encoding the antibody, a vector containing the nucleic acid sequence, a pharmaceutical composition and a kit. The monoclonal antibody can specifically bind to an IL17A protein with a high affinity, has a stronger ability to block the binding of IL17A and IL17A/F to the receptor IL17RA, and can be used for treating psoriasis, etc.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
Disclosed is a polyvalent human papillomavirus (HPV) immunogenicity composition for preventing disease or infections related to HPV. The polyvalent HPV immunogenicity composition contains: an HPV virus-like particle formed from assembling L1 proteins of HPV type 6, type 11, type 16, type 18, type 31, type 33, type 45, type 52, and type 58; and one or more HPV virus-like particles formed from assembling L1 proteins of other pathogenic HPV types. In one embodiment, the one or more other pathogenic HPV types are selected from HPV type 35, type 39, type 51, type 56, or type 59. In one embodiment, at least one of the described HPV virus-like particles is a chimeric HPV virus-like particle, the chimeric HPV virus-like particle containing one or more chimeric HPV L1 proteins.
The present invention relates to a chimeric papillomavirus L1 protein and a polynucleotide encoding same, as well as HPV virus-like particles and a preparation method therefor. The chimeric papillomavirus L1 protein comprises an N-terminal fragment derived from the first-type papillomavirus L1 protein, wherein the N-terminal fragment maintains the immunogenicity of the L1 protein corresponding to HPV types; and a C-terminal fragment derived from the second-type papillomavirus L1 protein and having better characteristics of expression quantity and solubility than those of other types of L1 protein, wherein the chimeric papillomavirus L1 protein has the immunogenicity of the L1 protein corresponding to HPV types. The chimeric papillomavirus L protein has a higher expression quantity and a better solubility, and can be used for the large-scale production of vaccines.
The present invention relates to the field of tumor immunotherapy, and relates to a humanized anti-VEGF Fab antibody fragment. Disclosed in the present invention are a nucleic acid sequence encoding the antibody fragment (comprising heavy/light chain variable regions), a vector containing the nucleic acid sequence, a pharmaceutical composition, and a kit. The anti-VEGF Fab antibody fragment disclosed in the present invention can be specifically bound to VEGF with high affinity, can block VEGF from binding to a receptor VEGFR2, and can also neutralize the proliferation effect of VEGF on HUVEC cells. Compared with the full-length structure, the antibody of the Fab fragment has stronger penetrability, and lower toxic and side effects such as gastrointestinal perforation, hypertension, and hemorrhage and cannot excite the complement cascade reaction, thereby reducing the risk of initiating intraocular inflammation and autoimmune inflammatory response. The antibody can be used to clinically treat various ocular diseases characterized by choroidal neovascularization, comprising but not limited to age-related macular degeneration (AMD), diabetic macular edema (DME), retinal edema, degenerative myopia, and choroidal neovascularization (CNV).
A chimeric human papillomavirus (HPV) type 51 L1 protein and polynucleotide coding same. Also involved are an HPV type 51 virus-like particle and a preparation method therefor. The chimeric HPV type 51 L1 protein comprises an N-terminal fragment derived from the HPV type 51 L1 protein, the N-terminal fragment maintaining the immunogenicity of the HPV type 51 L1 protein; and a C-terminal fragment derived from a type II papillomavirus L1 protein, the type II papillomavirus L1 protein having better expression quantity and solubility than other types of L1 proteins, wherein the chimeric HPV type 51 L1 protein has the immunogenicity of the HPV type 51 L1 protein. The chimeric HPV type 51 L1 protein has higher expression quantity and solubility, and can be applied to mass production of vaccines.
Provided is a humanized anti-VEGFR2 antibody drug. Also provided are a nucleic acid sequence (comprising a heavy/light chain variable region) encoding the antibody, a vector containing the nucleic acid sequence, a pharmaceutical composition, and a kit. The antibody can specifically bind to the sixth structural domain of VEGFR2, exerts a function independent of ligand VEGF-A, and can directly inhibit VEGFR2 from forming a dimer, thereby blocking tyrosine residue phosphorylation caused by the dimerization of an intracellular domain of VEGFR2 and a downstream signaling pathway. In addition, the antibody keeps a function of partially blocking VEGF-C and VEGF-D, and thus has a better angiogenesis inhibition function. The antibody can also activate the occurrence of an antibody-dependent cell-mediated cytotoxicity (ADCC) reaction in NK cells, inhibits tumor growth and tumor metastases, and can be used for clinically treating melanomas.
A chimeric human papillomavirus type 16 L1 protein, a polynucleotide encoding same, an HPV type 16 virus-like particle, and a preparation method therefor. The chimeric human papillomavirus type 16 L1 protein comprises an N-terminal fragment derived from an HPV type 16 L1 protein, the N-terminal fragment retaining the immunogenicity of the HPV type 16 L1 protein; and a C-terminal fragment derived from an L1 protein of a second type of papillomavirus having better expression and solubility characteristics compared to L1 proteins of other types of papillomavirus. The chimeric HPV type 16 L1 protein has the immunogenicity of the HPV type 16 L1 protein. The chimeric human papillomavirus type 16 L1 protein has a high expression level and high solubility and can be used in large-scale production of a vaccine.
The present invention relates to the field of tumor immunotherapy, and relates to a humanized anti-VEGF Fab antibody fragment. Disclosed in the present invention are a nucleic acid sequence encoding the antibody fragment (comprising heavy/light chain variable regions), a vector containing the nucleic acid sequence, a pharmaceutical composition, and a kit. The anti-VEGF Fab antibody fragment disclosed in the present invention can be specifically bound to VEGF with high affinity, can block VEGF from binding to a receptor VEGFR2, and can also neutralize the proliferation effect of VEGF on HUVEC cells. Compared with the full-length structure, the antibody of the Fab fragment has stronger penetrability, and lower toxic and side effects such as gastrointestinal perforation, hypertension, and hemorrhage and cannot excite the complement cascade reaction, thereby reducing the risk of initiating intraocular inflammation and autoimmune inflammatory response. The antibody can be used to clinically treat various ocular diseases characterized by choroidal neovascularization, comprising but not limited to age-related macular degeneration (AMD), diabetic macular edema (DME), retinal edema, degenerative myopia, and choroidal neovascularization (CNV).
Provided are a chimeric human papillomavirus type 6 L1 protein and a polynucleotide encoding same. Also provided are an HPV type 6 virus-like particle and a preparation method therefor. The chimeric human papillomavirus type 6 L1 protein comprises an N-terminal fragment derived from an HPV type 6 L1 protein, the N-terminal fragment retaining the immunogenicity of the HPV type 6 L1 protein; and a C-terminal fragment derived from an L1 protein of a second type of papillomavirus having better expression and solubility characteristics compared to L1 proteins of other types of papillomavirus. The chimeric HPV type 6 L1 protein has the immunogenicity of the HPV type 6 L1 protein. The chimeric human papillomavirus type 6 L1 protein has a high expression level and high solubility and can be used in large-scale production of a vaccine.
Disclosed are a chimeric human papillomavirus type 11 L1 protein and a polynucleotide encoding same, and an HPV type 11 virus-like particle and a preparation method therefor. The chimeric human papillomavirus type 11 L1 protein contains an N-terminus fragment derived from the HPV type 11 L1 protein, the N-terminus fragment having immunogenicity for the HPV type 11 L1 protein; and a C-terminus fragment derived from an L1 protein of a second type of papillomavirus, the L1 protein of the second type of papillomavirus having better expression and solubility characteristics compared to other types of L1 proteins. The chimeric HPV type 11 L1 protein has immunogenicity for the HPV type 11 L1 protein.
The present invention provides chimeric human papillomavirus 35 type L1 protein and polynucleotides encoding the same, and further provides HPV 35 type virus-like particles and a preparation method thereof. The chimeric human papillomavirus 35 type L1 protein comprises an N-terminal fragment derived from HPV 35 type L1 protein, the N-terminal fragment maintains immunogenicity of the HPV 35 type L1 protein; and a C-terminal fragment derived from a second type papillomavirus L1 protein, the second type papillomavirus L1 protein has better expression and solubility characteristics than other types of L1 protein; wherein the chimeric HPV35 type L1 protein has the immunogenicity of HPV 35 type L1 protein. The chimeric human papillomavirus 35 type L1 protein has higher expression and solubility, and can be used for mass production of vaccines.
Disclosed is a polyvalent human papillomavirus (HPV) immunogenicity composition for preventing disease or infections related to HPV. The polyvalent HPV immunogenicity composition contains: an HPV virus-like particle formed from assembling L1 proteins of HPV type 6, type 11, type 16, type 18, type 31, type 33, type 45, type 52, and type 58; and one or more HPV virus-like particles formed from assembling L1 proteins of other pathogenic HPV types. In one embodiment, the one or more other pathogenic HPV types are selected from HPV type 35, type 39, type 51, type 56, or type 59. In one embodiment, at least one of the described HPV virus-like particles is a chimeric HPV virus-like particle, the chimeric HPV virus-like particle containing one or more chimeric HPV L1 proteins.
Disclosed are a chimeric human papillomavirus type 39 L1 protein and a polynucleotide encoding same, and an HPV type 39 virus-like particle and a preparation method therefor. The chimeric human papillomavirus type 39 L1 protein contains an N-terminus fragment derived from the HPV type 39 L1 protein, the N-terminus fragment having immunogenicity for the HPV type 39 L1 protein; and a C-terminus fragment derived from an L1 protein of a second type of papillomavirus, the L1 protein of the second type of papillomavirus having better expression and solubility characteristics compared to other types of L1 proteins. The chimeric HPV type 39 L1 protein has immunogenicity for the HPV type 39 L1 protein.
The present invention relates to a chimeric papillomavirus L1 protein and a polynucleotide encoding same, as well as HPV virus-like particles and a preparation method therefor. The chimeric papillomavirus L1 protein comprises an N-terminal fragment derived from the first-type papillomavirus L1 protein, wherein the N-terminal fragment maintains the immunogenicity of the L1 protein corresponding to HPV types; and a C-terminal fragment derived from the second-type papillomavirus L1 protein and having better characteristics of expression quantity and solubility than those of other types of L1 protein, wherein the chimeric papillomavirus L1 protein has the immunogenicity of the L1 protein corresponding to HPV types. The chimeric papillomavirus L protein has a higher expression quantity and a better solubility, and can be used for the large-scale production of vaccines.
Disclosed are a chimeric human papillomavirus type 18 L1 protein and a polynucleotide encoding same, and an HPV type 18 virus-like particle and a preparation method therefor. The chimeric human papillomavirus type 18 L1 protein contains an N-terminus fragment derived from the HPV type 18 L1 protein, the N-terminus fragment having immunogenicity for the HPV type 18 L1 protein; and a C-terminus fragment derived from an L1 protein of a second type of papillomavirus, the L1 protein of the second type of papillomavirus having better expression and solubility characteristics compared to other types of L1 proteins. The chimeric HPV type 18 L1 protein has immunogenicity for the HPV type 18 L1 protein.
Disclosed are a chimeric human papillomavirus type 45 L1 protein and a polynucleotide encoding same, and an HPV type 45 virus-like particle and a preparation method therefor. The chimeric human papillomavirus type 45 L1 protein contains an N-terminus fragment derived from the HPV type 45 L1 protein, the N-terminus fragment having immunogenicity for the HPV type 45 L1 protein; and a C-terminus fragment derived from an L1 protein of a second type of papillomavirus, the L1 protein of the second type of papillomavirus having better expression and solubility characteristics compared to other types of L1 proteins. The chimeric HPV type 45 L1 protein has immunogenicity for the HPV type 45 L1 protein.
A chimeric human papilloma virus (HPV) 52 type L1 protein and a polynucleotide encoding same, HPV 52 type virus-like particles and a preparation method therefor. The chimeric HPV 52 type L1 protein comprises: N-terminal fragments derived from the HPV 52 type L1 protein, the N-terminal fragments maintaining the immunogenicity of the HPV 52 type L1 protein; and C-terminal fragments derived from a second type papilloma virus L1 protein, the second type papilloma virus L1 protein having properties of higher L1 protein expression quantity and better solubility in comparison to any other type L1 protein. The chimeric HPV 52 type L1 protein has the immunogenicity of the HPV 52 type L1 protein. The chimeric HPV 52 type L1 protein has higher expression quantity and better solubility, and can be used for large scale production of vaccines.
Disclosed are a chimeric human papillomavirus 56-type L1 protein and a polynucleotide encoding same, as well as HPV 56-type virus-like particles and a preparation method therefor. The chimeric human papillomavirus 56-type L1 protein comprises an N-terminal fragment derived from the 56-type L1 protein, wherein the N-terminal fragment maintains the immunogenicity of the HPV 56-type L1 protein; and a C-terminal fragment derived from the second-type papillomavirus L1 protein and having better characteristics of expression quantity and solubility than those of other types of L1 protein, wherein the chimeric HPV 56-type L1 protein has the immunogenicity of the HPV 56-type L1 protein. The chimeric human papillomavirus 56-type L1 protein has a higher expression quantity and a better solubility, and can be used for the large-scale production of vaccines.
The present invention belongs to the field of tumor immunotherapy, and relates to a humanized monoclonal antibody that binds to VEGF. Provided are a nucleic acid sequence (comprising heavy/light chain variable regions) encoding the antibody, a vector comprising the nucleic acid sequence, a pharmaceutical composition and a kit. The antibody provided may specifically bind to VEGF with high affinity and block the binding of VEGF to a receptor VEGFR2. The antibody may also neutralize proliferation effects of VEGF165 alone and multiple VEGF subtypes together on HUVEC cells, and may be used for clinical treatment of tumors, comprising but not limited to: colorectal cancer.
The present application provides a multivariable dosing method for use in treating a high-EGFR expression cancer. In particular, the present application discloses a multivariable dosing method for treating a high EGFR expression cancer in a subject having such need, comprising: in a first treatment period, giving a first dosage of an anti-EGFR antibody or an antigen binding fragment thereof to the subject; and subsequently in a second treatment period, giving a second dosage of the anti-EGFR antibody or the antigen binding fragment thereof to the subject.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention belongs to the field of tumor immunotherapy, and relates to a humanized monoclonal antibody that binds to VEGF. Provided are a nucleic acid sequence (comprising heavy/light chain variable regions) encoding the antibody, a vector comprising the nucleic acid sequence, a pharmaceutical composition and a kit. The antibody provided may specifically bind to VEGF with high affinity and block the binding of VEGF to a receptor VEGFR2. The antibody may also neutralize proliferation effects of VEGF165 alone and multiple VEGF subtypes together on HUVEC cells, and may be used for clinical treatment of tumors, comprising but not limited to: colorectal cancer.
Disclosed are a chimeric human papillomavirus type 31 L1 protein and a polynucleotide encoding same, and an HPV type 31 virus-like particle and a preparation method therefor. The chimeric human papillomavirus type 31 L1 protein contains an N-terminus fragment derived from the HPV type 31 L1 protein, the N-terminus fragment having immunogenicity for the HPV type 31 L1 protein; and a C-terminus fragment derived from an L1 protein of a second type of papillomavirus, the L1 protein of the second type of papillomavirus having better expression and solubility characteristics compared to other types of L1 proteins. The chimeric HPV type 31 L1 protein has immunogenicity for the HPV type 31 L1 protein.
The present invention pertains to the field of tumor immunotherapy, and provides a recombinant humanized anti-VEGFR2 antibody drug. The present invention further provides a nucleic acid sequence encoding the antibody, a vector containing the nucleic acid sequence, a pharmaceutical composition, and a kit. The antibody provided by the present invention can specifically bind to tumor cells and block the effects of VEGF-A, VEGF-C, and VEGF-D at the same time, and thus has a better inhibitory effect on angiogenesis. The antibody can also activate NK cells to produce antibody-dependent cytotoxicity reactions and inhibit the growth and metastasis of tumors, and can be used for the clinical treatment of melanoma.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A chimeric human papillomavirus type 58 L1 protein, a polynucleotide encoding same, an HPV type 58 virus-like particle, and a preparation method therefor. The chimeric human papillomavirus type 58 L1 protein comprises an N-terminal fragment derived from an HPV type 58 L1 protein, the N-terminal fragment retaining the immunogenicity of the HPV type 58 L1 protein; and a C-terminal fragment derived from an L1 protein of a second type of papillomavirus having better expression and solubility characteristics compared to L1 proteins of other types of papillomavirus. The chimeric HPV type 58 L1 protein has the immunogenicity of the HPV type 58 L1 protein. The chimeric human papillomavirus type 58 L1 protein has a high expression level and high solubility and can be used in large-scale production of a vaccine.
The present invention provides a recombinant humanized monoclonal antibody against programmed cell death receptor-1 (PD-1) or an antigen-binding fragment thereof, which can be used in tumor or cancer immunotherapy. The invention also provides nucleic acid sequences encoding said antibody or antigen-binding fragment thereof, vectors containing said nucleic acid sequences, pharmaceutical compositions and kits.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A recombinant humanized monoclonal antibody against programmed cell death protein-1 (PD-1) or an antigen-binding fragment thereof useful for tumor or cancer immunotherapy. Also provided are a nucleic acid sequence encoding the antibody or an antigen-binding fragment thereof, a vector containing the nucleic acid sequence, a pharmaceutical composition, and a kit.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Provided is a neutralising antibody which binds to and neutralises an H7 type influenza A virus. The nucleotide sequences of the light and heavy chain variable regions of the antibody are at least 75% identical to the nucleotide sequence of any one of SEQ ID NO: 38-55, 58 or 59, and the antibody can neutralise a human infection H7N9 influenza A virus haemagglutinin protein. Also provided is an efficient expression method for integrating an antibody into a cell such as a CHO cell, and a use for the antibody, a related haemagglutinin protein antigen binding fragment and an epitope in the diagnosis, treatment and prevention of human infection H7N9 influenza A virus infection.
